Earnings call transcript: Edwards Lifesciences Q1 2026 beats expectations

Edwards Lifesciences delivered a strong Q1 2026 beat, with revenue of $1.65 billion up 12.7% year over year and adjusted EPS of $0.78 versus $0.73 expected. The company raised full-year 2026 sales growth guidance to 9%-11% from 8%-10% and lifted adjusted EPS guidance to $2.95-$3.05, supported by strength in TAVR and TMTT and a 400 bps FX tailwind to reported growth. Shares rose modestly after hours to $81.66 after closing the regular session down 2.15%.

Analysis

EW’s print is less about one quarter and more about a subtle inflection in the earnings algorithm: a higher mix of structurally advantaged therapies plus a cleaner operating cadence is starting to offset FX and launch drag. The key second-order effect is that management is now effectively monetizing the fact that procedure adoption is becoming evidence-led rather than price-led, which should support both ASP resilience and a longer runway for penetration in under-treated structural heart segments.

The competitive backdrop looks better for EW than the headline share discussion implies. In TAVR, the most important dynamic is not just competitor attrition; it is that the category is shifting toward earlier intervention and lifetime management, where long-duration clinical data and referral infrastructure matter more than acute device features. That favors EW’s installed base, but also creates a lagged benefit for CMS policy changes: if access broadens, the incremental cases should disproportionately accrue to the best-capitalized, best-trained operator network rather than to the most aggressive pricing strategy.

TMTT is the bigger medium-term upside lever. The market still appears to underwrite it as a single-product growth story, but the portfolio is moving toward a platform model with repair + replacement + next-gen launches, which should lift account density and lower marginal commercial cost over the next 12-18 months. The contrarian risk is execution, not demand: launch complexity, center training, and evidence timing can create quarter-to-quarter noise, so the multiple can rerate before the revenue line fully catches up.

The main reversal trigger is not a macro slowdown; it is a disappointment in trial readouts or a slowdown in conversion from awareness to procedures, which would expose the fact that a lot of the growth narrative is still evidence-pull rather than pure volume elasticity. For now, the setup is strongest into the next two catalysts: CMS NCD clarity and additional TMTT/TAVR data, both of which could extend the rerating if they reinforce access and durability.

Key Decisions for Investors

• Long EW on 1-3 month horizon on any post-earnings consolidation under current levels; upside comes from guide credibility and continued multiple expansion as investors reprice the durability of structural heart growth.
• Buy EW Jan-2027 calls or call spreads to express the 12-18 month TMTT platform story; risk/reward improves if the market continues to underappreciate multi-product account expansion.
• Pair trade: long EW vs short a basket of broader med-tech names with slower organic growth and less evidence-supported penetration; EW should sustain a premium as the market rewards visible procedure growth and capital returns.
• Add on dips ahead of the CMS NCD draft decision; that event is a positive catalyst for access and could drive a second leg higher if the policy direction confirms easier TAVR utilization.
• Use a stop-loss around any material trial disappointment or guidance rollback; the key risk is that valuation is pulling forward 2027+ growth, so evidence slippage could compress the multiple quickly.